You are here

Article Text

Article menu
Download PDFPDF
Letter
Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis
  1. Emma P K Yu1,
  2. Andrew J K Ostor1,
  3. Frances C Hall2
  1. 1Addenbrooke’s Hosptial, Cambridge, UK
  2. 2University of Cambridge Department of Clinical Medicine, Addenbrooke’s Hospital, Cambridge, UK
  1. Correspondence to:
    Dr F C Hall
    Box 157, University of Cambridge Department of Clinical Medicine, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK; fch22{at}medschl.cam.ac.uk

https://doi.org/10.1136/ard.2006.057604

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We report the case of a patient with limited cutaneous systemic sclerosis, who developed progressive digital gangrene. This responded rapidly to bosentan.

    A 38-year-old, previously well, male non-smoker presented with an ischaemic left index finger. On examination the distal left index finger was cyanosed; sclerodactyly and facial telangectasia were also noted. Investigations revealed haemoglobin 10.7 g/dl (normocytic); erythrocyte sedimentation rate 94 mm in the first hour; normal C-reactive protein levels; positive antinuclear, anticentromere and anti-Ro antibodies; normal complement components; no anticardiolipin antibodies, lupus anticoagulant activity or cryoglobulin; negative blood cultures; normal chest radiograph and ECG; arteriogram of the left arm revealed no arterial occlusion and was consistent with small vessel disease; and endoscopy …

    View Full Text

    Footnotes

    • Funding: FCH is funded by the Arthritis Research Campaign, Cambridge Arthritis Research Endeavour and The Evelyn Trust.

    • Competing interests: FCH has received funding from Actelion for a part-time research nurse.